IT202000004747A1 - COMPOSITION FOR USE IN THERAPY, IN PARTICULAR FOR THE TREATMENT OF ANXIETY - Google Patents
COMPOSITION FOR USE IN THERAPY, IN PARTICULAR FOR THE TREATMENT OF ANXIETY Download PDFInfo
- Publication number
- IT202000004747A1 IT202000004747A1 IT102020000004747A IT202000004747A IT202000004747A1 IT 202000004747 A1 IT202000004747 A1 IT 202000004747A1 IT 102020000004747 A IT102020000004747 A IT 102020000004747A IT 202000004747 A IT202000004747 A IT 202000004747A IT 202000004747 A1 IT202000004747 A1 IT 202000004747A1
- Authority
- IT
- Italy
- Prior art keywords
- weight
- percentage
- total weight
- composition according
- euphrasia
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 27
- 208000019901 Anxiety disease Diseases 0.000 title claims description 9
- 230000036506 anxiety Effects 0.000 title claims description 8
- 238000002560 therapeutic procedure Methods 0.000 title claims description 5
- 241000201295 Euphrasia Species 0.000 claims description 11
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 11
- 235000011922 Passiflora incarnata Nutrition 0.000 claims description 11
- 241001070941 Castanea Species 0.000 claims description 10
- 235000014036 Castanea Nutrition 0.000 claims description 10
- 241000208341 Hedera Species 0.000 claims description 10
- 241000218996 Passiflora Species 0.000 claims description 10
- 235000011925 Passiflora alata Nutrition 0.000 claims description 10
- 235000000370 Passiflora edulis Nutrition 0.000 claims description 10
- 235000013750 Passiflora mixta Nutrition 0.000 claims description 10
- 235000013731 Passiflora van volxemii Nutrition 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 244000141009 Hypericum perforatum Species 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 5
- 230000036651 mood Effects 0.000 claims description 5
- 230000036642 wellbeing Effects 0.000 claims description 5
- 241000546188 Hypericum Species 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 3
- 235000014037 Castanea sativa Nutrition 0.000 description 1
- 240000007857 Castanea sativa Species 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 244000215554 Nepeta hederacea Species 0.000 description 1
- 235000011755 Nepeta hederacea Nutrition 0.000 description 1
- 240000008440 Passiflora incarnata Species 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
CAMPO TECNICO DELL?INVENZIONE TECHNICAL FIELD OF THE INVENTION
La presente invenzione riguarda una nuova composizione, in particolare per l?uso nella terapia di pazienti, pi? in particolare per la cura dell?ansia, per il miglioramento dell?umore, per il rilassamento, per alleviare la tristezza e per migliorare il sonno e del senso di benessere in determinati pazienti. The present invention relates to a new composition, in particular for use in the therapy of patients, more? in particular for the treatment of anxiety, for the improvement of mood, for relaxation, to relieve sadness and to improve sleep and the sense of well-being in certain patients.
STATO DELLA TECNICA ANTERIORE STATE OF THE PRIOR ART
Sono stati proposti molte composizioni per il trattamento dell?ansia. Many compositions have been proposed for the treatment of anxiety.
Tuttavia, tali composizioni non riescono ad alleviare in maniera efficace i sintomi dell'ansia. Peraltro, le stesse composizioni richiedono costosi procedimenti produttivi che si riflettono negativamente sul prezzo finale del prodotto da somministrare. However, such compositions fail to effectively relieve symptoms of anxiety. Moreover, the same compositions require expensive production processes which negatively affect the final price of the product to be administered.
SCOPI DELL?INVENZIONE AIMS OF THE INVENTION
Uno scopo della presente invenzione ? quello di fornire una nuova composizione. A purpose of the present invention? to provide a new composition.
Un altro scopo della presente invenzione ? quello di fornire una nuova composizione per l?uso nella terapia in pazienti, in particolare per l?uso nel trattamento o nella cura dell'ansia, per il miglioramento dell?umore, per il rilassamento, per il trattamento o per alleviare la tristezza, per migliorare il sonno e/o del senso di benessere in pazienti in determinati pazienti. Another object of the present invention? to provide a novel composition for use in therapy in patients, particularly for use in the treatment or cure of anxiety, for the improvement of mood, for relaxation, for treatment or for the alleviation of sadness, to improve sleep and / or sense of well-being in patients in certain patients.
Un altro scopo della presente invenzione ? quello di fornire una composizione come sopra indicato che sia semplice e facile da ottenere. Another object of the present invention? that of providing a composition as indicated above which is simple and easy to obtain.
Un altro scopo della presente invenzione ? quello di fornire una composizione come sopra indicato che sia economica da realizzare. Another object of the present invention? that of providing a composition as indicated above which is economical to make.
Conformemente ad un aspetto della presente invenzione ? prevista una composizione secondo la rivendicazione 1. According to an aspect of the present invention? provided a composition according to claim 1.
Conformemente ad un altro aspetto della presente invenzione ? prevista una capsula secondo la rivendicazione 9. According to another aspect of the present invention? a capsule according to claim 9 is provided.
Conformemente ad un ulteriore aspetto della presente invenzione ? prevista una confezione secondo la rivendicazione 10. According to a further aspect of the present invention? a package according to claim 10 is provided.
Le rivendicazioni dipendenti si riferiscono a caratteristiche vantaggiose dell?invenzione. The dependent claims refer to advantageous features of the invention.
ESEMPI DI REALIZZAZIONE DELL?INVENZIONE EXAMPLES OF REALIZATION OF THE INVENTION
La presente invenzione riguarda un preparato o una composizione comprendente i seguenti componenti: The present invention relates to a preparation or a composition comprising the following components:
- arancio (Citrus sinensis), ad esempio in una percentuale in peso tra 15,4% e 25,4% sul peso totale, - orange (Citrus sinensis), for example in a percentage by weight between 15.4% and 25.4% of the total weight,
- castagno (Castanea sativa), ad esempio in una percentuale in peso tra 15,4% e 25,4% sul peso totale, - chestnut (Castanea sativa), for example in a percentage by weight between 15.4% and 25.4% of the total weight,
- eufrasia (Euphrasia), ad esempio in una percentuale in peso tra 11,3% e 21,3% sul peso totale, - Euphrasia (Euphrasia), for example in a percentage by weight between 11.3% and 21.3% of the total weight,
- edera terrestre (Glechoma hederacea), ad esempio in una percentuale in peso tra 7,2% e 17,2% sul peso totale, - land ivy (Glechoma hederacea), for example in a percentage by weight between 7.2% and 17.2% of the total weight,
- iperico (Hypericum perforatum), ad esempio in una percentuale in peso tra 9,3% e 19,3% sul peso totale, - St. John's wort (Hypericum perforatum), for example in a percentage by weight between 9.3% and 19.3% of the total weight,
- passiflora (Passiflora incarnata), ad esempio in una percentuale in peso tra 11,3% e 21,3% sul peso totale, e - passionflower (Passiflora incarnata), for example in a percentage by weight between 11.3% and 21.3% of the total weight, and
Vantaggiosamente, le percentuali dei suddetti componenti sono come di seguito indicato: - arancio in una percentuale in peso tra 19,4% e 21,4% sul peso totale, Advantageously, the percentages of the aforementioned components are as indicated below: - orange in a percentage by weight between 19.4% and 21.4% of the total weight,
- castagno in una percentuale in peso tra 19,4% e 21,4% sul peso totale, - chestnut in a percentage by weight between 19.4% and 21.4% of the total weight,
- eufrasia in una percentuale in peso tra 15,3% e 17,3% sul peso totale, - euphrasia in a percentage by weight between 15.3% and 17.3% of the total weight,
- edera terrestre in una percentuale in peso tra 11,2% e 13,2% sul peso totale, - land ivy in a percentage by weight between 11.2% and 13.2% of the total weight,
- iperico in una percentuale in peso tra 13,3% e 15,3% sul peso totale, - St. John's wort in a percentage by weight between 13.3% and 15.3% of the total weight,
- passiflora in una percentuale in peso tra 15,3% e 17,3% sul peso totale. - passionflower in a percentage by weight between 15.3% and 17.3% of the total weight.
Una composizione preferita secondo la presente invenzione comprende i suddetti componenti alle percentuali in peso come riportate qui di seguito: A preferred composition according to the present invention comprises the aforementioned components at the percentages by weight as reported below:
- arancio in una percentuale in peso tra 20,4% sul peso totale, - orange in a percentage by weight between 20.4% of the total weight,
- castagno in una percentuale in peso tra 20,4% sul peso totale, - chestnut in a percentage by weight between 20.4% of the total weight,
- eufrasia in una percentuale in peso tra 16,3% sul peso totale, - euphrasia in a percentage by weight between 16.3% of the total weight,
- edera terrestre in una percentuale in peso tra 12,2% sul peso totale, - land ivy in a percentage by weight between 12.2% of the total weight,
- iperico in una percentuale in peso tra 14,3% sul peso totale, - hypericum in a percentage by weight between 14.3% of the total weight,
- passiflora in una percentuale in peso tra 16,3% sul peso totale. - passionflower in a percentage by weight between 16.3% of the total weight.
Peraltro, almeno uno tra arancio, castagno, eufrasia, edera terrestre, iperico e passiflora ? presente sotto forma di estratto secco. Di preferenza, tutti tali componenti sono presenti sotto forma di estratti secchi. Moreover, at least one among orange, chestnut, euphrasia, terrestrial ivy, St. John's wort and passionflower? present in the form of dry extract. Preferably, all such components are present in the form of dry extracts.
Se ? presente l?arancio, anch?esso ? vantaggiosamente presente sotto forma di estratto secco. Un preparato o una composizione secondo la presente invenzione ? principalmente per l?uso nella terapia, in particolare per l?uso nel trattamento o nella cura dell?ansia e/o per il miglioramento dell?umore e/o per il rilassamento e/o per il trattamento o e/o per il trattamento o per alleviare la tristezza e/o per migliorare il sonno e/o del senso di benessere in pazienti. Self ? present the orange, too? advantageously present in the form of dry extract. A preparation or a composition according to the present invention? primarily for use in therapy, particularly for use in the treatment or cure of anxiety and / or for the improvement of mood and / or for relaxation and / or for treatment or and / or for treatment or to relieve sadness and / or to improve sleep and / or sense of well-being in patients.
Peraltro, una composizione in accordo con la presente invenzione pu? essere somministrata in capsule, ad esempio in capsule ciascuna di peso tra circa 0,4 e circa 0,6 g, volendo circa 0,5 g. On the other hand, a composition in accordance with the present invention can? be administered in capsules, for example in capsules each weighing between about 0.4 and about 0.6 g, about 0.5 g if desired.
In merito a ci?, una confezione potrebbe comprende tra 200 e 300 capsule, ad esempio 240 capsule. Regarding this, a package could comprise between 200 and 300 capsules, for example 240 capsules.
Per l?ottenimento di una composizione secondo la presente invenzione, si possono ad esempio essiccare le foglie dei componenti sopra indicati, dopodich? si polverizzano le foglie essiccate in modo da ottenere un preparato di consistenza polverosa con granulometria omogenea fine. To obtain a composition according to the present invention, it is possible, for example, to dry the leaves of the components indicated above, after which the leaves of the components indicated above can be dried. the dried leaves are pulverized in order to obtain a powdery consistency preparation with a fine homogeneous particle size.
Per l?incapsulamento della composizione si pu? invece seguire un procedimento standard. La composizione secondo la presente invenzione, in particolare sotto forma di capsule ? stata somministrata, nell?arco di un anno, ad una serie di pazienti, chiaramente umani, e si ? avuto modo di riscontrare che dopo tre settimane continue di somministrazione si verificava un miglioramento dell?umore e si rilevava un rilassamento e una diminuzione dell?ansia dei pazienti umani. For the encapsulation of the composition you can? instead follow a standard procedure. The composition according to the present invention, in particular in the form of capsules? was administered, over a year, to a series of patients, clearly human, and yes? was able to find that after three continuous weeks of administration there was an improvement in mood and there was a relaxation and a decrease in anxiety in human patients.
In particolare, si ? avuto modo di notare una netta diminuzione degli episodi di tristezza nei pazienti sottoposti al trattamento, mentre miglioravano il sonno, e il senso di benessere in generale. In particular, yes? noticed a clear decrease in episodes of sadness in the patients undergoing the treatment, while they improved sleep, and the sense of well-being in general.
In generale, la somministrazione di una composizione secondo la presente invenzione migliorava lo stato di ansia dei rispettivi pazienti. In general, the administration of a composition according to the present invention improved the anxiety state of the respective patients.
Il trattamento ? stato condotto in particolare somministrando da 1 a 3 capsule al mattino, da 1 a 2 a pranzo e da 1 a 3 il pomeriggio, sapendo che sono necessarie circa 2 ore per apprezzarne l?efficacia. The treatment ? It was conducted in particular by administering from 1 to 3 capsules in the morning, from 1 to 2 at lunch and from 1 to 3 in the afternoon, knowing that it takes about 2 hours to appreciate their effectiveness.
Modifiche e varianti dell?invenzione sono possibili entro l?ambito di protezione definito dalle rivendicazioni. Modifications and variants of the invention are possible within the protection scope defined by the claims.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000004747A IT202000004747A1 (en) | 2020-03-06 | 2020-03-06 | COMPOSITION FOR USE IN THERAPY, IN PARTICULAR FOR THE TREATMENT OF ANXIETY |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000004747A IT202000004747A1 (en) | 2020-03-06 | 2020-03-06 | COMPOSITION FOR USE IN THERAPY, IN PARTICULAR FOR THE TREATMENT OF ANXIETY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT202000004747A1 true IT202000004747A1 (en) | 2021-09-06 |
Family
ID=71575513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102020000004747A IT202000004747A1 (en) | 2020-03-06 | 2020-03-06 | COMPOSITION FOR USE IN THERAPY, IN PARTICULAR FOR THE TREATMENT OF ANXIETY |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT202000004747A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013186220A1 (en) * | 2012-06-11 | 2013-12-19 | Bioactor B.V. | Compositions comprising hesperidin and/or apigenin i.a. for medical use or for use in treatment of sleeping disorders |
| US20140322369A1 (en) * | 2011-12-23 | 2014-10-30 | Horphag Research Ip (Qr) Ltd | Ellagitannins Rich Extracts Composition |
| CA2920841A1 (en) * | 2016-02-16 | 2017-08-16 | David Ellery | Herbal formulation for treating chronic fatigue syndrome |
-
2020
- 2020-03-06 IT IT102020000004747A patent/IT202000004747A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140322369A1 (en) * | 2011-12-23 | 2014-10-30 | Horphag Research Ip (Qr) Ltd | Ellagitannins Rich Extracts Composition |
| WO2013186220A1 (en) * | 2012-06-11 | 2013-12-19 | Bioactor B.V. | Compositions comprising hesperidin and/or apigenin i.a. for medical use or for use in treatment of sleeping disorders |
| CA2920841A1 (en) * | 2016-02-16 | 2017-08-16 | David Ellery | Herbal formulation for treating chronic fatigue syndrome |
Non-Patent Citations (3)
| Title |
|---|
| GUREVICH MICHAEL I ET AL: "An Individualized Approach to Treatment-Resistant Bipolar Disorder: A Case Series", JOURNAL OF SCIENCE AND HEALING, ELSEVIER, GB, vol. 12, no. 4, 16 April 2016 (2016-04-16), pages 237 - 245, XP029595154, ISSN: 1550-8307, DOI: 10.1016/J.EXPLORE.2016.04.001 * |
| POPPENGA R H: "Herbal medicine: Potential for intoxication and interactions with conventional drugs", CLINICAL TECHNIQUES IN SMALL ANIMAL PRACTICE, SAUNDERS, PHILADELPHIA, PA, US, vol. 17, no. 1, 1 February 2002 (2002-02-01), pages 6 - 18, XP004970120, ISSN: 1096-2867, DOI: 10.1053/SVMS.2002.27785 * |
| WEISS R F ED - WEISS R F: "THE NERVOUS SYSTEM", 1 January 1985, HERBAL MEDICINE. TRANSLATION OF EDITION 6 OF LEHRBUCH DER PHYTOTHERAPIE BY MEUSS A. R, BEACONSFIELD, BEACONSFIELD PUBLISHERS, GB, PAGE(S) 280 - 291, 307/308, XP002049848 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xie et al. | Neuroprotective effect of ginsenoside-Rg1 on cerebral ischemia/reperfusion injury in rats by downregulating protease-activated receptor-1 expression | |
| KR101780692B1 (en) | Composition comprising natural mixture extract for preventing lose of hair or promoting growth of hair | |
| Liu et al. | Green tea polyphenols alleviate early BBB damage during experimental focal cerebral ischemia through regulating tight junctions and PKCalpha signaling | |
| Tanwar et al. | Aloe Vera and its uses in Dentistry | |
| Zhang et al. | Gold nanoparticles synthesized from Curcuma wenyujin inhibits HER-2/neu transcription in breast cancer cells (MDA-MB-231/HER2) | |
| DE10297736T5 (en) | Medicines for the prevention and treatment of bone fractures and osteoporosis | |
| IT202000004747A1 (en) | COMPOSITION FOR USE IN THERAPY, IN PARTICULAR FOR THE TREATMENT OF ANXIETY | |
| Zorko et al. | Efficacy of a polyphenolic extract from silver fir (Abies alba) bark on psoriasis: A randomised, double-blind, placebo-controlled trial | |
| KR20200136207A (en) | Composition for anti-allergy comprising extract of lithospermum erythrorhizon | |
| IT202000004123A1 (en) | COMPOSITION FOR USE IN THERAPY, ESPECIALLY FOR THE TREATMENT OF DEPRESSION | |
| IT202000009370A1 (en) | Composition for use in therapy, in particular for the treatment of overweight, obesity and for the reduction of excess body fat | |
| CN103349120A (en) | Health protection tea made of two chrysanthemums | |
| CN101310733A (en) | Medicine composition for treating the cerebrovascular disease and preparation method thereof | |
| Mishra et al. | Role of nutraceuticals in metabolic syndrome | |
| KR20170125481A (en) | Composition for increasing salivary secretion, or prevention, improvement or treatment of xerostomia of disorder of salivation comprising curcuma xanthorrhiza extract or xanthorrhizol | |
| Narule et al. | Formulation and Evaluation of Poly Herbal Hair Oil | |
| BR112015027985B1 (en) | ORAL COSMETIC USE OF A COMBINATION OF ACTIVE AGENTS AND COSMETIC PROCESS | |
| Gochoo et al. | The Effect of Musk on Neurons in the Pattern of Ischemic Stroke | |
| CN103212009A (en) | Medicine for treating cardiovascular and cerebtovascular diseases | |
| JP2018177748A (en) | Agent for activating glucose metabolism of astrocyte | |
| CN107334988B (en) | Traditional Chinese medicine composition for treating pulmonary abscess | |
| CN102085210B (en) | Medicinal composition for treating cerebral infarction | |
| DE102004041270A1 (en) | A capillary action system containing application differential differentiation compositions and their use | |
| IT202100015242A1 (en) | Oral composition for the prevention and/or treatment of disorders associated with menopause | |
| DE102015002709A1 (en) | New use of acetylsalicylic acid and a derivative thereof |